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To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were:
chemotherapy-naı ¨ve, small-cell lung cancer (SCLC), good performance status (PS: 0–2), agep75 years, and adequate organ function.
The patients’ characteristics were: male/female¼56/5; PS 0/1/2¼19/38/4; median age (range)¼68 years(51–75 years); limited
disease (LD)/extensive disease (ED)¼27/34. The patients received irinotecan (50mgm
 2) on days 1, 8, and 15, and carboplatin
(AUC 5, Chatelut formula) on day 1 every 4 weeks. In total, 61 patients were eligible and all were evaluated. In all, 31 patients were
treated with four or more courses of chemotherapy. Of the patients, 17 showed a complete response (CR), 34 showed a partial
response (PR), nine had stable disease (SD), and one had progressive disease (PD). The overall response rate was 84% (95%
confidence interval (CI), 72–91%; LD 89%, ED 79%) and the CR rate was 28% (95%CI, 17–41%; LD 37%, ED 21%). The median
time to tumour progression was 6.1 (LD 6.4, ED 5.4) months. The medial survival time was 15.0 (LD 20.0, ED 9.7) months, and the
2-year and 5-year survival rates were 31.1% (LD 48.1%, ED 17.7%) and 9.5% (LD 11.1%, ED 5.9%), respectively. Grade 3 or 4
leucopenia, neutropenia, thrombocytopenia, anaemia, and diarrhoea occurred in 33, 74, 41, 39, and 13% of cases, respectively. In
conclusion, the combination of irinotecan and carboplatin is an active and well-tolerated regimen in cases of SCLC.
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Irinotecan hydrochloride is a water-soluble prodrug that is
metabolized to the active metabolite SN-38, which inhibits the
function of DNA topoisomerase I in cancer cells (Hsiang and
Liu, 1988; Hertzberg et al, 1989). Irinotecan displays antitumour
activity in various cancer cells in vitro, and has been used in
the treatment of human cancers including lung cancer (Masuda
et al, 1996). Preclinical studies demonstrated synergism and
noncross resistance between platinum agents and irinotecan or
SN-38 (Kanzawa et al, 1990; Kano et al, 1993; Fukuda et al, 1996).
In small-cell lung cancer (SCLC), clinical trials with cisplatin and
weekly doses of irinotecan yielded a relatively high response rate of
84% (Kudoh et al, 1998) and demonstrated effectiveness in a
recent phase III study (Noda et al, 2002).
Carboplatin is a platinum derivative with less renal toxicity,
and to which caused less nausea and vomiting than cisplatin (Rose
and Schurig, 1985; Lokich and Anderson, 1998), and has been
combined with other newer agents in chemotherapy for SCLC
(Go and Adjei, 1999; Simon and Wagner, 2003). Accordingly, we
conducted a phase I trial with carboplatin and weekly doses of
irinotecan, and found that 11 of 13 SCLC patients had an objective
response, the response rate being 85% (complete response (CR),
31%; partial response (PR), 54%) (Fukuda et al, 1999). Pharma-
codynamic studies have been performed to predict the clearance
and administer the appropriate dose of carboplatin in individual
patients (Egorin et al, 1985; Calvert et al, 1989; Chatelut et al, 1995;
Duffull and Robinson, 1997; Mountain and Dresler, 1997). In a
prior phase I study, we prospectively evaluated the Chatelut
formula, and reported that the predicted carboplatin clearance
(CL) was closely correlated with the actual CL, and the actual AUCs
of carboplatin nearly reached the target AUC of 5 (Fukuda et al,
1999).
Based on these results, we conducted a phase II study of
irinotecan and carboplatin therapy for SCLC. The main objectives
of the study were to determine the efficacy and safety of irinotecan
and carboplatin therapy in previously untreated patients with
SCLC.
PATIENTS AND METHODS
The study protocol was approved by the Ethical Committee of
Nagasaki University School of Medicine. This study is an inde-
pendent collaborative (nonsponsored) group study.
Patients
Eligibility criteria for patients in this study included the following:
a histologically confirmed diagnosis of SCLC; no prior
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schemotherapy or radiotherapy; agep75 years; Eastern Cooperative
Oncology Group (ECOG) performance status (PS)p2; life expec-
tancy greater than 12 weeks; adequate bone marrow function
(leucocyte count X4000ml
 1, platelet count X10.0 10
4ml
 1,a n d
hemoglobin level X10.0gdl
 1); serum bilirubin level p1.25mgdl
 1;
ALT and AST levels p2t i m e st h en o r m a lu p p e rl i m i t ;s e r u m
creatinine level p10
5mgdl
 1 and PaO2 X70mmHg; no medical
problems severe enough to prevent compliance with the protocol;
and written informed consent.
Limited disease (LD) was defined as disease confined to one
hemithorax with regional lymph node metastasis, including
hilar mediastinal and supraclavicular nodes, whether ipsilateral
or contralateral. Extensive disease (ED) included all patients
with disease sites that were not eligible for the limited-stage
classification.
Treatment
Based on our phase I study (Fukuda et al, 1999), patients received
50mgm
 2 of irinotecan on days 1, 8, and 15, and carboplatin
with a target AUC of 5mgmin
 1ml
 1 on day 1. The dose of carbo-
platin was determined by multiplying the target AUC of 5 by the
carboplatin CL, which was predicted with the Chatelut formula
(Chatelut et al, 1995) using the Jaffe ´ method to measure serum
creatinine. The value of serum creatinine obtained using the
enzymatic method (X) were converted to that using the Jaffe ´
method (Y) with the formula Y¼0.97Xþ0.27. Then, the estimated
CL (mlmin
 1) were calculated in those institutions as follows:
CL¼0.134 weightþ(218 weight (1 0.00457 age) (1 0.314 
sex)) 113 1.03 10
 4/(s Crþ0.276) (with weight in kg, age in
years, and sex¼0i fm a l ea n ds e x ¼1 if female). In Japanese
institutions, the measurement method of serum creatinine was
changed to the enzymatic method. Carboplatin was administered
during a 60-min intravenous infusion of 250ml of 5% dextrose
followed by 500ml of normal saline as a 2-h infusion. This was
f o l l o w e db ya9 0 - m i ni n t r a v e n o u si n f u s i o no fi r i n o t e c a ni n2 5 0 m l
of 5% dextrose. Irinotecan was not administered on day 8 or 15 in the
cycle if the leucocyte count was o3 10
9l
 1, the platelet count was
o100 10
9l
 1, or the patient had diarrhoea on those days. The next
cycle commenced after the leucocyte and platelet counts reached at
least 3 10
9 and 100 10
9l
 1, respectively. This chemotherapy was
repeated every 4 weeks. The patients were planned to receive four
cycles of chemotherapy. After four cycles of chemotherapy, standard
thoracic irradiation at 60Gy was administered to patients with LD.
Patient evaluation
Tumour staging was performed, as described previously (Fukuda
et al, 1999), using a tumour-node-metastasis system (Mountain
and Dresler, 1997). Before the first cycle, a blood cell count,
urinalysis, and biochemistry tests were performed to assess renal
and hepatic function, and electrolytes. This monitoring was
repeated during treatment, while other investigations were
repeated, as necessary, to evaluate marker lesions. After the
completion of treatment, each disease was assessed and tumours
were restaged. The eligibility, assessability, and response of each
patient were determined by extramural reviewers.
Tumour response and toxicities were classified according
to World Health Organization criteria (WHO, 1979). A CR
represented the disappearance of any evidence of tumours for at
least 4 weeks. A PR was defined as a 50% or more reduction in
the sum of the product of the greatest perpendicular diameter of
all lesions for at least 4 weeks. Stable disease (SD) was defined
as a o50% reduction or p25% increase in the products of the
greatest perpendicular diameters of all the lesions, but without any
evidence of new lesions. Progressive disease (PD) was defined as
an increase of 425% or the appearance of new lesions.
Statistical analyses
The primary end point of this study was to estimate the objective
response rate. The two-stage accrual design described by Simon
(1987) was used. Assuming an overall response rate of 70% for
standard therapy, a target response rate of 85% was established.
a¼0.05, b¼0.20, and the estimated required number of patients
was more than 49. Considering unfitness, drop out and disconti-
nuation, the sample size of this study was determined to be 60.
Overall survival was calculated by the Kaplan–-Meier method
(Kaplan and Meier, 1958).
RESULTS
A total of 61 patients from 10 institutions were enrolled in this
trial, between January 1998 and November 2000. All patients
received irinotecan/carboplatin therapy and were evaluated for
toxicity, response, and survival. The patient characteristics are
shown in Table 1. In all, 27 patients (44%) had limited disease (LD)
and 34 patients (56%) had ED.
Treatment administration
A total of 194 cycles of this therapy were administered: one cycle in
six patients, two cycles in 11, three in 13, four in 28, and five in
three patients. In all, 37 irinotecan administrations were skipped
on day 8, 55 on day 15, and 16 on both days. The major reasons for
omissions on days 8 and 15 were leucopenia 47 cases, diarrhoea
16 cases, thrombocytopenia nine cases, leucopenia/diarrhoea and
leucopenia/thrombocytopenia four cases and reduction in PS three
cases. The administration rate (actual/planned number of treat-
ment) of irinotecan on days 8 and 15 was 81 and 72%, respectively.
The average treatment delay was 1.4 days per cycle. The dose
intensity (DI) of irinotecan was 30.0mgm
 2week
 1, which was
80.0% of the projected DI. The DI rate relative to the projected DI
of carboplatin was 95.4%.
Efficacy
All 61 patients were evaluated for response. Objective tumour
response was observed in 51 patients with 17 complete and 34 PR,
with an overall response rate of 84% (95% confidence interval (CI):
72–91%) and CR rate of 28% (95% CI: 17–41%) (Table 2). Stable
disease was observed in nine (15%) patients, and the remaining
one (2%) patient had PD.
The overall survival of all 61 patients is shown in Figure 1. The
median potential follow-up time was 55.0 (range, 40.1–73.5)
months. The median follow-up for the five patients who survived
was 58.8 (range, 54.8–63.5) months. The other 56 patients died
Table 1 Patient characteristics (n¼61)
Characteristics LD ED Total
No. of patients 27 34 61
Age (year)
Median 67 69 68
Range 51–74 52–75 51–75
Sex
Male 24 32 56
Female 3 2 5
PS (ECOG)
01 2 7 1 9
1 1 42 43 8
2 134
PS¼performance status; ECOG¼Eastern Cooperative Oncology Group.
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sduring the follow-up period. Median time to tumour progression
was 6.1 (LD 6.4, ED 5.4) months. Median survival time (MST) was
15.0 (LD 20.0, ED 9.7) months, and the 1-, 2-, 3-, 4-, and 5-year
survival rates were 57.4, 31.1, 18.0, 14.8, and 9.5%, respectively.
Survival rates for each stage are also shown in Figure 1.
Toxicity
The toxicities noted during the treatment are listed in Table 3. All
61 patients were assessable for toxicity. In all, 51 (84%) patients
experienced grade 3 or 4 haematological toxicity, and 21 (34%)
had grade 4. The principal grade 3 or 4 haematological toxicity
was neutropenia in 45 (74%) patients, and the principal grade 4
toxicities were neutropenia and thrombocytopenia in 17 (28%) and
nine (15%) patients, respectively. Febrile neutropenia occurred
in five (8%) patients. Concerning nonhaematological toxicity, eight
(13%) patients experienced grade 3 or 4 diarrhoea, one of whom
had grade 4 with fever and grade 3 ileus during the first cycle and
was obliged to finish with the treatment. Interstitial pneumonitis
occurred in one (2%) patient, who had a high fever for 2 days from
day 24 of the third cycle. This patient had hypoxaemia with
ground-glass opacity in their chest X-ray on day 28. The patient
improved with corticosteroid therapy. No other severe toxicities
were observed in the liver, kidney, nervous system, urinary
bladder, skin, or mucous membrane.
DISCUSSION
In the present trial of irinotecan/carboplatin therapy for SCLC,
the overall and CR rates, MST, and 2-year survival rate were 84,
28, 15.0 months, and 31.1%, respectively. Although these results
indicate that irinotecan/carboplatin have comparable activity with
irinotecan/cisplatin, which yielded values of 84, 29, 13.2 months,
and 19.3%, respectively, for SCLC (Kudoh et al, 1998), the results
differed with each stage.
In previously untreated ED-SCLC patients, platinum-based
chemotherapy remains the mainstay. A recent Japan Clinical
Oncology Group (JCOG) phase III study (Noda et al, 2002)
revealed that patients randomized to the irinotecan/cisplatin arm
did significantly better than the group randomized to the cisplatin/
etoposide arm (MST 12.8 vs 9.4 months; 2-year survival rate 19.5
vs 5.2%, respectively), and revived the good survival results of the
irinotecan/cisplatin phase II study (MST 13.0 months and 2-year
survival rate 21.7% in ED) (Kudoh et al, 1998). The MST of the
present study in ED patients, 9.7 months, fell short of that of
irinotecan/cisplatin, and was near that of cisplatin/etoposide. It is
encouraging that the patients were older (median age, 69 vs 63
years) and included fewer females (6 vs 14–26%) than in these
other studies, and the 2-year survival rate (17.7%) and response
rate (79%) were good and similar to those for irinotecan/cisplatin
rather than cisplatin/etoposide. Recent large randomized trials of
cisplatin/etoposide with or without newer cytotoxic agents have
demonstrated a MST of 8.0–10.6 months in previously untreated
patients with ED-SCLC (De Marinis et al, 2003, Georgoulias
et al, 2004; Niell et al, 2005). In addition, a recent meta-analysis
of randomized trials demonstrated that patients who received
a regimen containing cisplatin had a significant increase in the
probability of response and survival (Pujol et al, 2000; Hotta et al,
2004). Thus, we consider irinotecan/carboplatin of value as a
convenient carboplatin-containing two-drugs regimen with similar
activity to cisplatin-containing regimens, except irinotecan/cispla-
tin in patients with ED-SCLC. More recently, a multicentre, large
randomized phase III trial (n¼331) was conducted to confirm the
results of the JCOG study (Hanna et al, 2005). The patients were
randomized to either irinotecan/cisplatin or cisplatin/etoposide
and there was no statistically significant difference in overall
survival (MST 9.3 vs 10.2 months). The DI delivered of irinotecan
was higher in this trial (39 vs 36.2mgm
 2wk
 1), however, the
DI (mgm
 2wk
 1) rate of irinotecan to cisplatin were lower
(39/18¼2.17 vs 36.2/14.3¼2.53), and the response rate of 48% in
irinotecan/cisplatin arm of this study was lower than that of the
JCOG (84.4%) and our study (79%). Thus, we consider that the
insufficiency use of irinotecan in Hanna’s-modified irinotecan/
cisplatin regimen or the ethnic difference might have caused the
study failure.
In previously untreated LD-SCLC, it has emerged that con-
current thoracic chemoradiotherapy (CRT) is superior to sequen-
tial CRT when platinum/etoposide regimens are used for
chemotherapy (Simon and Wagner, 2003). When the irinotecan/
cisplatin regimen was used, ordinary concurrent CRT was deemed
unacceptable (Yokoyama et al, 1998), and unexpectedly poor
results of the sequential CRT in LD-SCLC with a MST of 14.3
Table 2 Response
Stage n CR PR SD PD RR (%) CR rate (%)
LD 27 10 14 2 1 89 37
ED 34 7 20 7 0 79 21
Total 61 17 34 9 1 84 28
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease; RR¼response rate; LD¼limited disease; ED¼extensive disease.
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Figure 1 Overall survival curve of the 61 patients enrolled in the present
study. A solid (___) line show the curve of 27 patients with LD, and dotted
(_ _ _) lines show the curve of 34 patients with ED.
Table 3 Toxicities (n¼61)
WHO grade (n)
Adverse event 1 2 3 4 Grade 3/4 (%)
Haematological
Anaemia 13 18 18 6 39
Leucopenia 7 30 16 4 33
Neutropenia 2 11 28 17 74
Thrombocytopenia 15 11 16 9 41
Nonhaematological
Diarrhoea 21 12 5 3 13
Elevated transaminases 8 2 0 0 0
Nausea/vomiting 27 13 5 — 8
Fever 10 7 0 0 0
Alopecia 33 13 0 0 0
Pneumonitis 1 0 1 0 2
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smonths and 2-year survival rate of 17.5% (Kudoh et al, 1998) may
even suggest unsuitableness of irinotecan/platinum for radio-
therapy. To resolve this issue, we administered a split-course early
concurrent radiotherapy combined with irinotecan/cisplatin (Oka
et al, 2001, 2002; Nagashima et al, 2004). Although the phase II
study in LD-SCLC is not finished yet, the MST and 2-year survival
rate were 25.2 months and 56.2%, respectively, in our phase I study
(Oka et al, 2002). Alternatively, we have used late sequential
radiotherapy combined with irinotecan/carboplatin. The MST in
the present study did not reach that obtained with cisplatin/
etoposide or in early concurrent radiotherapy studies (Takada
et al, 2002; Segawa et al, 2003) but was similar to values in other
cooperative studies (Hanna et al, 2002; Edelman et al, 2004; Schild
et al, 2004) and the 2-year survival rate nearly reached the level
obtained in two early concurrent studies (Takada et al, 2002;
Segawa et al, 2003). Furthermore, the present study included rather
advanced cases of LD in which more than half of the lung fields
were affected, and in some ways, these cases are a good indication
of the present regimen in practical use.
The main toxicity of our irinotecan/carboplatin therapy was
haematological. Comparing grade 3 or higher toxicities in the
present study with those for non-small-cell lung cancer (Fukuda
et al, 2004), the incidences of neutropenia, thrombocytopenia,
anaemia, and diarrhoea were higher (74, 41, 39, 13 vs 60, 25, 32,
and 7%, respectively), and those of leucopenia, nausea/vomiting,
and pneumonitis were comparable (33, 8, 2 vs 32, 10, 2%,
respectively). This difference was caused by the difference in
therapeutic period between SCLC and NSCLC. Platelet transfusion
was performed only twice in 136 cycles of irinotecan/carboplatin
therapy. Comparing grade 3 or higher toxicities with irinotecan/
cisplatin (Noda et al, 2002; Takada et al, 2002), the incidence of
thrombocytopenia was higher, and the incidences of nausea/
vomiting and diarrhoea were lower in the present study.
In conclusion, our multicentre phase II trial demonstrated the
usefulness of irinotecan/carboplatin in chemotherapy for SCLC.
This regimen is a convenient noncisplatin treatment comparable in
terns of the probability of response and survival with other
regimens for SCLC.
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